<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Med Res</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Med Res</journal-id><journal-id journal-id-type="publisher-id">Elmer Press</journal-id><journal-title-group><journal-title>Journal of Clinical Medicine Research</journal-title></journal-title-group><issn pub-type="ppub">1918-3003</issn><issn pub-type="epub">1918-3011</issn><publisher><publisher-name>Elmer Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">29416576</article-id><article-id pub-id-type="pmc">5798264</article-id><article-id pub-id-type="doi">10.14740/jocmr3067e</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Association of SIRT-1 Gene Polymorphism and Vitamin D Level in Egyptian Patients With Rheumatoid Arthritis</article-title><alt-title alt-title-type="short">SIRT-1 Gene Polymorphism and Vitamin D in RA</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Sabry</surname><given-names>Dina</given-names></name><xref ref-type="aff" rid="Aa">a</xref><xref ref-type="corresp" rid="CORf">f</xref></contrib><contrib contrib-type="author"><name><surname>Kaddafy</surname><given-names>Shereen Rashad</given-names></name><xref ref-type="aff" rid="Ab">b</xref></contrib><contrib contrib-type="author"><name><surname>Abdelaziz</surname><given-names>Ahmed Ali</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Nassar</surname><given-names>Abdelfattah Kasem</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Rayan</surname><given-names>Mohamed Moneer</given-names></name><xref ref-type="aff" rid="Ac">c</xref></contrib><contrib contrib-type="author"><name><surname>Sadek</surname><given-names>Sadek Mostafa</given-names></name><xref ref-type="aff" rid="Ad">d</xref></contrib><contrib contrib-type="author"><name><surname>Abou-Elalla</surname><given-names>Amany A</given-names></name><xref ref-type="aff" rid="Ae">e</xref></contrib></contrib-group><aff id="Aa"><label>a</label>Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt</aff><aff id="Ab"><label>b</label>Medical Biochemistry and Molecular Biology, Faculty of Medicine, Fayoum University, Al Fayoum, Egypt</aff><aff id="Ac"><label>c</label>Department of Rheumatology and Rehabilitation, Faculty of Medicine, Al-Azhar University, Cairo, Egypt</aff><aff id="Ad"><label>d</label>Department of internal medicine, Faculty of Medicine, Al-Azhar University, Cairo, Egypt</aff><aff id="Ae"><label>e</label>Technology of Medical Laboratory, Faculty of Applied Medical Sciences, Misr University for Science and Technology, 6th of October City, Egypt</aff><author-notes><corresp id="CORf"><label>f</label>Corresponding Author: Dina Sabry, Medical Biochemistry and Molecular Biology, Faculty of Medicine, Cairo University, Cairo, Egypt. Email: <email>dinasabry@kasralainy.edu.eg</email></corresp></author-notes><pub-date pub-type="ppub"><month>3</month><year>2018</year></pub-date><pub-date pub-type="epub"><day>26</day><month>1</month><year>2018</year></pub-date><volume>10</volume><issue>3</issue><fpage>189</fpage><lpage>195</lpage><history><date date-type="received"><day>15</day><month>5</month><year>2017</year></date><date date-type="accepted"><day>16</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>Copyright 2018, Sabry et al.</copyright-statement><copyright-year>2018</copyright-year><license license-type="open access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background</title><p>We investigated SIRT-1 genetic variant and its association with vitamin D level in Egyptian patients with rheumatoid arthritis (RA).</p></sec><sec><title>Methods</title><p>Seventy Egyptian subjects were enrolled in our study and divided into two groups: RA group (n = 50 patients) and healthy control group (n = 20 subjects). Five milliliter blood sample was withdrawn from each subject followed by laboratory investigation and DNA extraction for SIRT-1 gene polymorphism assessment (rs7895833 A&#x0003e;G, rs7069102 C&#x0003e;G and rs2273773 C&#x0003e;T) and vitamin D level expression.</p></sec><sec><title>Results</title><p>There was statistically significant difference between rheumatoid cases and controls with regard to vitamin D level with 88% of cases showing insufficient vitamin D versus all controls showing sufficient level. SIRT-1 different SNPs rs2273773, rs7895833and rs7069102 genotype frequencies were statistically significant in RA compared to control group (P = 0.001). There was no statistically significant difference between different genotypes of rs2273773, rs7895833 and rs7069102 with regard to vitamin D level.</p></sec><sec><title>Conclusion</title><p>We concluded that there is a strong association between SIRT-1 polymorphism genotyping and RA. Vitamin D level was insufficient in Egyptian patients with RA.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>SIRT-1 polymorphism</kwd><kwd>Vitamin D</kwd><kwd>Rheumatoid arthritis</kwd><kwd>Egypt</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Rheumatoid arthritis (RA) is an autoimmune disease, resulting in a chronic, systemic inflammatory disorder [<xref rid="R01" ref-type="bibr">1</xref>]. It is a disease affecting joint cartilage and bone with synovial inflammation and infiltration of inflammatory immune cells [<xref rid="R02" ref-type="bibr">2</xref>].</p><p>Vitamin D deficiency was shown to have a role in increased levels of proinflammatory cytokines and it plays a very important role in the reduction of inflammation, by suppression of prostaglandin (PG) action, inhibition of p38 stress kinase signaling, and the production of proinflammatory cytokines and inhibition of nuclear factor-&#x003ba;B (NF-&#x003ba;B) signaling [<xref rid="R03" ref-type="bibr">3</xref>].</p><p>The SIRT-1 gene is located on the 10q21.3 chromosome [<xref rid="R04" ref-type="bibr">4</xref>]. SIRTs are a conserved family of NAD+ dependent histone deacetylases (HDACs) and mono-ADP-ribosyltransferases that target histones, transcription factors and coregulators to adapt gene expression to the cellular energy state [<xref rid="R05" ref-type="bibr">5</xref>]. HDACs are enzymes inhibiting gene expression by reversing acetylation of histone proteins. In mammals, seven sirtuin genes, SIRT-1 to SIRT-7, have been identified. Among them, SIRT-1 is best characterized so far. It has been shown that it regulates transcription factors such as members of the forkhead transcription factor FOXO family [<xref rid="R06" ref-type="bibr">6</xref>], p53 [<xref rid="R07" ref-type="bibr">7</xref>], NF-&#x003ba;B [<xref rid="R08" ref-type="bibr">8</xref>], the DNA repair factor Ku70 [<xref rid="R9" ref-type="bibr">9</xref>], and the transcriptional coactivator p300 [<xref rid="R10" ref-type="bibr">10</xref>].</p><p>SIRT-1 is found in many tissues such as pancreas, liver, skeletal muscle, brain and adipose tissue. It plays a crucial role in various human diseases such as cardiovascular diseases, inflammation, aging, neurodegenerative disease, non-alcoholic fatty liver disease (NAFLD), amyotrophic lateral sclerosis (ALS), and even cancers [<xref rid="R11" ref-type="bibr">11</xref>]. It has been reported that it is a potential therapy for NAFLD [<xref rid="R12" ref-type="bibr">12</xref>], ALS [<xref rid="R13" ref-type="bibr">13</xref>], kidney disease [<xref rid="R14" ref-type="bibr">14</xref>], and pulmonary disease [<xref rid="R15" ref-type="bibr">15</xref>].</p><p>We, therefore, conducted the SIRT-1 gene polymorphism (rs7895833 A&#x0003e;G, rs7069102 C&#x0003e;G and rs2273773 C&#x0003e;T) in the present study to investigate SIRT-1 genetic variants and its association with vitamin D levels in Egyptian patients with RA.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Subjects</title><p>The present study included 70 Egyptian subjects who were divided into two groups: RA group (n = 50 patients) and healthy control group (n = 20 subjects).</p><p>RA group included 38 men and 12 women with a mean age of 40.1 &#x000b1; 11.5 years. Patients were clinically diagnosed by physical examination and laboratory investigations at the Faculty of Medicine, Al-Azhar and Cairo Universities. In addition, the control group included nine men and 11 women with a mean age of 43.3 &#x000b1; 9.8 years. They were recruited from healthy subjects admitted to the same hospital.</p><p>Written informed consent was obtained from all subjects enrolled in the study. Approval for this study was not required in accordance with the policy of our institution.</p></sec><sec id="s2b"><title>Biochemical investigations</title><p>Blood samples of all subjects were centrifuged for 5 min at 4 &#x000b0;C, followed by the removal of plasma and then stored at -20 &#x000b0;C. The following biochemical parameters were determined in both the control and RA groups by standard laboratory methods in the Faculty of Medicine, Cairo University: complete blood picture, total bilirubin, direct bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), albumin, urea, creatinine, international normalized ratio (INR), and AFP. Whole blood samples of all subjects were analyzed for the genotypes of SIRT-1 and plasma for vitamin D level expression.</p></sec><sec id="s2c"><title>DNA isolation</title><p>The genomic DNA was extracted from whole peripheral blood sample using QIAamp DNA blood mini-kit extraction kit (Qiagen, Hilden, Germany) following the manufacturer&#x02019;s instructions.</p><p>All DNA samples were quantitated using the Nano Drop<sup>&#x000ae;</sup>-1000 spectrophotometer (Nanodrop Technologies, Inc., Wilmington, USA).</p></sec><sec id="s2d"><title>SIRT-1 genotyping</title><p>Genotyping was determined using real-time PCR (StepOne, Applied Biosystems, Foster City, USA). SIRT-1 SNPs including rs7895833 A&#x0003e;G in the promoter region, rs7069102 C&#x0003e;G in intron 4 and rs2273773 C&#x0003e;T in exon 5 (Cat No. 4351379) were analyzed in the extracted DNA by using specific primers and Taqman FAM and VIC probes (Taqman SNP genotyping assays, Applied Biosystems, Foster City, CA). The 25 &#x000b5;L PCR mixture included 20 ng of whole blood genomic extracted DNA and the following reagents: 0.5 &#x000b5;L FAM and VIC probes and primers (Taqman SNP genotyping assays), 12.5 &#x000b5;L Taqman universal master mix II No UNG (Cat No. 4440040) and DNase free water. The thermal cycling profile was 10 min at 95 &#x000b0;C for enzyme activation followed by 40 cycles of 15 s DNA denaturation at 95 &#x000b0;C, 20 s primers and probes annealing at 55 &#x000b0;C, and 30 s at 72 &#x000b0;C for the amplification step. The genotyping was analyzed with StepOne Applied Biosystem version 2.1 soft ware analysis.</p></sec><sec id="s2e"><title>Vitamin D serum level assessment</title><p>Vitamin D plasma level was detected by ELISA 25-OH vitamin D kit according to instructions of manufactures (DRG, international Inc., USA). The data are expressed as ng/mL. Grading of vitamin D levels was done as follows: &#x02265; 30 ng/mL (normal); 10 - 30 ng/mL (insufficiency); &#x02264; 10 ng/mL (deficiency).</p></sec><sec id="s2f"><title>Statistical analysis</title><p>Data were collected and coded to facilitate data manipulation and double entered into Microsoft Access and data analysis was performed using SPSS software version 18 in windows 7. Simple descriptive analysis in the form of numbers and percentages for qualitative data, and arithmetic means as central tendency measurement, standard deviations as measure of dispersion for quantitative parametric data, and inferential statistic test: Student&#x02019;s <italic>t</italic>-test used to compare measures of two independent groups of quantitative data were conducted. P value &#x02264; 0.05 was considered the cut-off value for significance.</p></sec></sec><sec id="s3"><title>Results</title><p>Fifty patients suffering from RA were enrolled in this study together with 20 subjects as controls. Among the 50 patients, 38 (76%) were men and 12 (24%) were women. The average age was 40.1 &#x000b1; 11.5 years. In the control group, nine (45%) were men and 11 (55%) were women; the average age was 43.3 &#x000b1; 9.8 years. While there was no significant difference between groups with regard to age, a significant difference was found as regards gender. The age and gender distribution of the persons included in the study and their P values are given in <xref ref-type="table" rid="T1">Table 1</xref>. Laboratory investigations in different study groups are given in <xref ref-type="table" rid="T1">Table 1</xref> in which there is statistically significant difference with P-value &#x0003c; 0.05 between rheumatoid cases and controls with regard to anti-CCP and vitamin D level, with high mean of anti-CCP, and low mean of vitamin D among RA patients.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Demographic Characteristics and Routine Investigations in Different Study Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">Rheumatoid cases (n = 50), mean &#x000b1; SD</th><th align="left" rowspan="1" colspan="1">Controls (n = 20), mean &#x000b1; SD</th><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Sex</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Males</td><td align="left" valign="top" rowspan="1" colspan="1">38 (76%)</td><td align="left" valign="top" rowspan="1" colspan="1">9 (45%)</td><td align="left" valign="top" rowspan="1" colspan="1">0.023</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Females</td><td align="left" valign="top" rowspan="1" colspan="1">12 (24%)</td><td align="left" valign="top" rowspan="1" colspan="1">11 (55%)</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">40.1 &#x000b1; 11.5</td><td align="left" valign="top" rowspan="1" colspan="1">43.3 &#x000b1; 9.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.289</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Complete blood count</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;RBCs (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">92.4 &#x000b1; 26.6</td><td align="left" valign="top" rowspan="1" colspan="1">100.7 &#x000b1; 16.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.199</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Hb (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">13.4 &#x000b1; 1.9</td><td align="left" valign="top" rowspan="1" colspan="1">13.8 &#x000b1; 1.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.429</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TLC (10/mm)</td><td align="left" valign="top" rowspan="1" colspan="1">6.6 &#x000b1; 2</td><td align="left" valign="top" rowspan="1" colspan="1">5.7 &#x000b1; 0.98</td><td align="left" valign="top" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;PLT (10/mm)</td><td align="left" valign="top" rowspan="1" colspan="1">272.9 &#x000b1; 94.7</td><td align="left" valign="top" rowspan="1" colspan="1">239.1 &#x000b1; 68.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.150</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver function</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;ALT (IU/L)</td><td align="left" valign="top" rowspan="1" colspan="1">44.6 &#x000b1; 13.6</td><td align="left" valign="top" rowspan="1" colspan="1">32.5 &#x000b1; 5.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AST (IU/L)</td><td align="left" valign="top" rowspan="1" colspan="1">52.6 &#x000b1; 10.1</td><td align="left" valign="top" rowspan="1" colspan="1">30.9 &#x000b1; 5.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Total bilirubin (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">0.72 &#x000b1; 0.17</td><td align="left" valign="top" rowspan="1" colspan="1">0.85 &#x000b1; 0.23</td><td align="left" valign="top" rowspan="1" colspan="1">0.036</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Direct bilirubin (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">0.22 &#x000b1; 0.10</td><td align="left" valign="top" rowspan="1" colspan="1">0.23 &#x000b1; 0.11</td><td align="left" valign="top" rowspan="1" colspan="1">0.851</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Albumin (g/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">4.1 &#x000b1; 0.48</td><td align="left" valign="top" rowspan="1" colspan="1">4.3 &#x000b1; 0.41</td><td align="left" valign="top" rowspan="1" colspan="1">0.058</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other investigations</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Alkaline phosphatase (IU/L)</td><td align="left" valign="top" rowspan="1" colspan="1">67.2 &#x000b1; 26</td><td align="left" valign="top" rowspan="1" colspan="1">71.4 &#x000b1; 23</td><td align="left" valign="top" rowspan="1" colspan="1">0.536</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Creatinine (mg/dL)</td><td align="left" valign="top" rowspan="1" colspan="1">0.91 &#x000b1; 0.29</td><td align="left" valign="top" rowspan="1" colspan="1">0.95 &#x000b1; 0.18</td><td align="left" valign="top" rowspan="1" colspan="1">0.02</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CRP (mg/L)</td><td align="left" valign="top" rowspan="1" colspan="1">0.24 &#x000b1; 0.13</td><td align="left" valign="top" rowspan="1" colspan="1">0.23 &#x000b1; 0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.707</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;INR</td><td align="left" valign="top" rowspan="1" colspan="1">1.07 &#x000b1; 0.10</td><td align="left" valign="top" rowspan="1" colspan="1">1.12 &#x000b1; 0.13</td><td align="left" valign="top" rowspan="1" colspan="1">0.143</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Anti-CCP (U/ML)</td><td align="left" valign="top" rowspan="1" colspan="1">61.7 &#x000b1; 26</td><td align="left" valign="top" rowspan="1" colspan="1">6.9 &#x000b1; 4.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TSH (mIU/L)</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 &#x000b1; 0.99</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 &#x000b1; 0.77</td><td align="left" valign="top" rowspan="1" colspan="1">0.799</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AFP (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">2.9 &#x000b1; 2.1</td><td align="left" valign="top" rowspan="1" colspan="1">1.7 &#x000b1; 0</td><td align="left" valign="top" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Vit D (ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">17.9 &#x000b1; 9.2</td><td align="left" valign="top" rowspan="1" colspan="1">42.2 &#x000b1; 11.8</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>Independent <italic>t</italic>-test: Pearson &#x003c7;<sup>2</sup> (exact). SD: standard deviation.</p></fn></table-wrap-foot></table-wrap><sec id="s3a"><title>Vitamin D level ANA titer</title><p><xref ref-type="table" rid="T2">Table 2</xref> illustrates that there is statistically significant difference between rheumatoid cases and controls as regards vitamin D level with 88% of cases showing insufficient vitamin D versus all controls showing sufficient level.</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>ANA Titer and Vitamin D Levels in Study Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Rheumatoid cases (n = 50)<hr/></th><th colspan="2" align="center" rowspan="1">Controls (n = 20)<hr/></th><th rowspan="2" align="left" colspan="1">P-value</th></tr><tr><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">ANA titer</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Low titer</td><td align="left" valign="top" rowspan="1" colspan="1">50</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1">-</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Vitamin D level</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Deficient (&#x0003c; 10 ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Insufficient (10 - 29 ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">44</td><td align="left" valign="top" rowspan="1" colspan="1">88%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Sufficient (30 - 100 ng/mL)</td><td align="left" valign="top" rowspan="1" colspan="1">3</td><td align="left" valign="top" rowspan="1" colspan="1">6%</td><td align="left" valign="top" rowspan="1" colspan="1">20</td><td align="left" valign="top" rowspan="1" colspan="1">100%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>On the other hand, there is no statistically significance difference with P-value &#x0003e; 0.05 as regards ANA titer.</p></sec><sec id="s3b"><title>Frequencies of SIRT-1 (rs2273773 C&#x0003e;T, rs7895833 A&#x0003e;G, and rs7069102 C&#x0003e;G) gene polymorphisms</title><p>The frequencies of genotypes and alleles in SIRT-1 gene in all groups are shown in <xref ref-type="table" rid="T3">Table 3</xref>. CC, TC and TT genotype frequencies of rs2273773 were 36%, 38% and 26%, respectively for the group with RA, and these were 60%, 40% and 0%, respectively for the control group (P = 0.000). While the frequencies of C and T alleles of the group with RA were 55% and 45%, these were 80% and 20% for the control group (P = 0.006).</p><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Distribution of Genotypes and Allelic Frequency Among Patients and Controls</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Rheumatoid cases (n = 50)<hr/></th><th colspan="2" align="center" rowspan="1">Controls (n = 20)<hr/></th><th rowspan="2" align="left" colspan="1">P-value</th></tr><tr><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th><th align="left" rowspan="1" colspan="1">No.</th><th align="left" rowspan="1" colspan="1">%</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">rs2273773 C&#x0003e;T</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">18</td><td align="left" valign="top" rowspan="1" colspan="1">36%</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CT</td><td align="left" valign="top" rowspan="1" colspan="1">19</td><td align="left" valign="top" rowspan="1" colspan="1">38%</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">40%</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TT</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Allele</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;C</td><td align="left" valign="top" rowspan="1" colspan="1">55</td><td align="left" valign="top" rowspan="1" colspan="1">55%</td><td align="left" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">80%</td><td align="left" valign="top" rowspan="1" colspan="1">0.006</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;T</td><td align="left" valign="top" rowspan="1" colspan="1">45</td><td align="left" valign="top" rowspan="1" colspan="1">45%</td><td align="left" valign="top" rowspan="1" colspan="1">8</td><td align="left" valign="top" rowspan="1" colspan="1">20%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7895833 A&#x0003e;G</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">27</td><td align="left" valign="top" rowspan="1" colspan="1">54%</td><td align="left" valign="top" rowspan="1" colspan="1">2</td><td align="left" valign="top" rowspan="1" colspan="1">10%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AG</td><td align="left" valign="top" rowspan="1" colspan="1">17</td><td align="left" valign="top" rowspan="1" colspan="1">34%</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">30%</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AA</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">12</td><td align="left" valign="top" rowspan="1" colspan="1">60%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Allele</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;G</td><td align="left" valign="top" rowspan="1" colspan="1">71</td><td align="left" valign="top" rowspan="1" colspan="1">71%</td><td align="left" valign="top" rowspan="1" colspan="1">10</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;A</td><td align="left" valign="top" rowspan="1" colspan="1">29</td><td align="left" valign="top" rowspan="1" colspan="1">29%</td><td align="left" valign="top" rowspan="1" colspan="1">30</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7069102 C&#x0003e;G</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">31</td><td align="left" valign="top" rowspan="1" colspan="1">62%</td><td align="left" valign="top" rowspan="1" colspan="1">0</td><td align="left" valign="top" rowspan="1" colspan="1">0%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CG</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1">26%</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">0.000</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">6</td><td align="left" valign="top" rowspan="1" colspan="1">12%</td><td align="left" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Allele</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;C</td><td align="left" valign="top" rowspan="1" colspan="1">25</td><td align="left" valign="top" rowspan="1" colspan="1">25%</td><td align="left" valign="top" rowspan="1" colspan="1">35</td><td align="left" valign="top" rowspan="1" colspan="1">87.5%</td><td align="left" valign="top" rowspan="1" colspan="1">&#x0003c; 0.001</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;&#x02003;&#x02003;G</td><td align="left" valign="top" rowspan="1" colspan="1">75</td><td align="left" valign="top" rowspan="1" colspan="1">75%</td><td align="left" valign="top" rowspan="1" colspan="1">5</td><td align="left" valign="top" rowspan="1" colspan="1">12.5%</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>GG, AG and AA genotype frequencies of rs7895833 were 54%, 34% and 12%, respectively for the group with RA, and these were 10%, 30% and 60% for the control group (P = 0.000). While the frequencies of G and A alleles of the group with RA were 71% and 29%, these were 25% and 75% for the control group (P &#x0003c; 0.001).</p><p>GG, CG and CC genotype frequencies of rs7069102 were 62%, 26% and 12%, respectively for the group with RA, and these were 0%, 25% and 75% for the control group (P = 0.000). The frequencies of G and C alleles of the group with RA were 75% and 25%, and these were 12.5% and 87.5% for the control group (P &#x0003c; 0.001).</p></sec><sec id="s3c"><title>Relationship between SIRT-1 gene polymorphisms and levels of vitamin D</title><p>There was no statistically significant difference with P-value &#x0003e; 0.05 between different genotypes of rs2273773, rs7895833 and rs7069102 as regards vitamin D level (<xref ref-type="table" rid="T4">Table 4</xref>).</p><table-wrap id="T4" orientation="portrait" position="float"><label>Table 4</label><caption><title>Comparisons of Vitamin D in Different SIRT-1 Polymorphisms Among Rheumatoid Patients</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Vitamin D<hr/></th><th rowspan="2" align="left" colspan="1">P-value</th></tr><tr><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">rs2273773</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TT</td><td align="left" valign="top" rowspan="1" colspan="1">17.3</td><td align="left" valign="top" rowspan="1" colspan="1">9.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TC</td><td align="left" valign="top" rowspan="1" colspan="1">16.3</td><td align="left" valign="top" rowspan="1" colspan="1">4.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">20.9</td><td align="left" valign="top" rowspan="1" colspan="1">13.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7895833</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">17.4</td><td align="left" valign="top" rowspan="1" colspan="1">6.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AG</td><td align="left" valign="top" rowspan="1" colspan="1">19.9</td><td align="left" valign="top" rowspan="1" colspan="1">13.5</td><td align="left" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AA</td><td align="left" valign="top" rowspan="1" colspan="1">13.9</td><td align="left" valign="top" rowspan="1" colspan="1">4.6</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7069102</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">15.9</td><td align="left" valign="top" rowspan="1" colspan="1">4.5</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CG</td><td align="left" valign="top" rowspan="1" colspan="1">22.1</td><td align="left" valign="top" rowspan="1" colspan="1">15.7</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">16.5</td><td align="left" valign="top" rowspan="1" colspan="1">5.2</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><p>There was no statistically significance difference with P-value &#x0003e; 0.05 between different genotypes rs2273773, rs7895833, and rs7069102 as regards anti-CCP level (<xref ref-type="table" rid="T5">Table 5</xref>). There is no correlation between vitamin D levels and any other study variables (<xref ref-type="table" rid="T6">Table 6</xref>).</p><table-wrap id="T5" orientation="portrait" position="float"><label>Table 5</label><caption><title>Comparisons of Anti-CCP in Different SIRT-1 Polymorphisms Among Rheumatoid Patients</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Anti-CCP<hr/></th><th rowspan="2" align="left" colspan="1">P-value</th></tr><tr><th align="left" rowspan="1" colspan="1">Mean</th><th align="left" rowspan="1" colspan="1">SD</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">rs2273773</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TT</td><td align="left" valign="top" rowspan="1" colspan="1">59.6</td><td align="left" valign="top" rowspan="1" colspan="1">23.4</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TC</td><td align="left" valign="top" rowspan="1" colspan="1">59.1</td><td align="left" valign="top" rowspan="1" colspan="1">17.4</td><td align="left" valign="top" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">68.5</td><td align="left" valign="top" rowspan="1" colspan="1">38.3</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7895833</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">67.9</td><td align="left" valign="top" rowspan="1" colspan="1">29.9</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AG</td><td align="left" valign="top" rowspan="1" colspan="1">58.9</td><td align="left" valign="top" rowspan="1" colspan="1">18.6</td><td align="left" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AA</td><td align="left" valign="top" rowspan="1" colspan="1">41.8</td><td align="left" valign="top" rowspan="1" colspan="1">13</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">rs7069102</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;GG</td><td align="left" valign="top" rowspan="1" colspan="1">58.2</td><td align="left" valign="top" rowspan="1" colspan="1">23.1</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CG</td><td align="left" valign="top" rowspan="1" colspan="1">71.7</td><td align="left" valign="top" rowspan="1" colspan="1">39</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CC</td><td align="left" valign="top" rowspan="1" colspan="1">58.2</td><td align="left" valign="top" rowspan="1" colspan="1">18.7</td><td align="left" valign="top" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap><table-wrap id="T6" orientation="portrait" position="float"><label>Table 6</label><caption><title>Correlation Between Vitamin D Levels With All Study Variables</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="left" colspan="1">Variables</th><th colspan="2" align="center" rowspan="1">Vitamin D<hr/></th></tr><tr><th align="left" rowspan="1" colspan="1">r</th><th align="left" rowspan="1" colspan="1">P-value</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Age (years)</td><td align="left" valign="top" rowspan="1" colspan="1">0.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Complete blood count</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;RBCs</td><td align="left" valign="top" rowspan="1" colspan="1">0.15</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Hb</td><td align="left" valign="top" rowspan="1" colspan="1">-0.11</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TLC</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td><td align="left" valign="top" rowspan="1" colspan="1">0.5</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;PLT</td><td align="left" valign="top" rowspan="1" colspan="1">0.02</td><td align="left" valign="top" rowspan="1" colspan="1">0.9</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Liver function</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;ALT</td><td align="left" valign="top" rowspan="1" colspan="1">-0.16</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AST</td><td align="left" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Total bilirubin</td><td align="left" valign="top" rowspan="1" colspan="1">0.27</td><td align="left" valign="top" rowspan="1" colspan="1">0.09</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Direct bilirubin</td><td align="left" valign="top" rowspan="1" colspan="1">0.25</td><td align="left" valign="top" rowspan="1" colspan="1">0.08</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Albumin</td><td align="left" valign="top" rowspan="1" colspan="1">-0.26</td><td align="left" valign="top" rowspan="1" colspan="1">0.07</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other routine investigations</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Alkaline phosphatase</td><td align="left" valign="top" rowspan="1" colspan="1">0.07</td><td align="left" valign="top" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Creatinine</td><td align="left" valign="top" rowspan="1" colspan="1">-0.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;PC</td><td align="left" valign="top" rowspan="1" colspan="1">0.04</td><td align="left" valign="top" rowspan="1" colspan="1">0.8</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;CRP</td><td align="left" valign="top" rowspan="1" colspan="1">-0.06</td><td align="left" valign="top" rowspan="1" colspan="1">0.6</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;INR</td><td align="left" valign="top" rowspan="1" colspan="1">0.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Other</td><td align="left" valign="top" rowspan="1" colspan="1"/><td align="left" valign="top" rowspan="1" colspan="1"/></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;Anti-CCP</td><td align="left" valign="top" rowspan="1" colspan="1">0.14</td><td align="left" valign="top" rowspan="1" colspan="1">0.4</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;TSH</td><td align="left" valign="top" rowspan="1" colspan="1">-0.16</td><td align="left" valign="top" rowspan="1" colspan="1">0.3</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">&#x02003;&#x02003;AFP</td><td align="left" valign="top" rowspan="1" colspan="1">-0.19</td><td align="left" valign="top" rowspan="1" colspan="1">0.2</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4"><title>Discussion</title><p>RA is a chronic inflammatory disease in which there is destruction of joint cartilage and bone. It is characterized by synovial hyperplasia, synovial inflammation, and infiltration of inflammatory immune cells [<xref rid="R02" ref-type="bibr">2</xref>].</p><p>Our data confirm that vitamin D deficiency is common in our Egyptian patients with RA. Vitamin D levels were found to be insufficient in 88% of cases and deficient in 6% of cases. This result is in agreement with previous reports on patients with RA from other ethnic groups [<xref rid="R16" ref-type="bibr">16</xref>, <xref rid="R17" ref-type="bibr">17</xref>].</p><p>No relationship was found between 25(OH)D and any other parameter in the routine investigations. This finding is in agreement with others studies [<xref rid="R18" ref-type="bibr">18</xref>].</p><p>It was proved that vitamin D deficiency may have a role in the increased levels of proinflammatory cytokines (IL6, IL17, interferon gamma, TNF alpha, etc.) and it plays a very important role in the reduction of inflammation, including suppression of prostaglandin (PG) action, inhibition of p38 stress kinase signaling, and the production of proinflammatory cytokines and inhibition of NF-&#x003ba;B signaling [<xref rid="R03" ref-type="bibr">3</xref>].</p><p>Another factor seems to have a role in production of such proinflammatory cytokines which is SIRT-1 gene, which also regulates transcription factors, DNA repair factor Ku70 and the transcriptional coactivator p300 [<xref rid="R06" ref-type="bibr">6</xref>, <xref rid="R07" ref-type="bibr">7</xref>, <xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>].</p><p>Thereby, SIRT-1 controls a broad range of cellular processes, including cell survival and inflammation [<xref rid="R19" ref-type="bibr">19</xref>]. SIRT-1 was found to be overexpressed in RA synovial tissues and it directly enhances proinflammatory cytokine production of synovial cells and inhibits apoptosis [<xref rid="R20" ref-type="bibr">20</xref>].</p><p>Therefore, we planned to investigate the different genotypes and allelic frequency of the SIRT-1 gene in patients with RA. In our study, we analyzed rs7895833, rs7069102 and rs2273773 polymorphisms in the SIRT-1 gene and associated these results with levels of vitamin D and anti-CCP in the studied groups.</p><p>A significant difference was found between TT, CT and CC genotypes of rs2273773 C&#x0003e;T. The incidence of CC (the wild genotype) was low in patients (36%) than in controls (60%), while the incidence of TT genotypes (the mutant genotype) in patients was higher (26%) than in control (0%).</p><p>Moreover, we found a significant difference between GG, AG and AA genotypes of rs7895833 A&#x0003e;G, in which the incidence of GG (the mutant genotype) was higher in patients (54%) than in controls (10%), while the incidence of AA genotypes (the wild genotype) in patients was lower (12%) than in control (60%). The GG (the mutant genotype) genotype of rs7069102 C&#x0003e;G showed higher frequency in patients (62%) than in controls (0%) and the CC (the wild genotype) genotype showed low frequency in patients (12%) than in controls (75%). Thus, the TT genotype of rs2273773, GG genotypes of rs7895833 and GG genotype of rs7069102 are high up in patients than in controls.</p><p>Therefore, this result may point out the strong relation of TT genotype of rs2273773, GG genotypes of rs7895833 and GG genotype of rs7069102 with RA. Further investigation is necessary to verify its role in remission and activity.</p><p>Regarding the allelic frequency of rs2273773, the C allele was dominant in the control group (80%), and formed about 55% of the RA group, while the T allele which was seen less frequently in the control group (20%), formed about 45% of the rheumatoid arthritis.</p><p>On the other hand, the G alleles of both rs7895833 and rs7069102 were dominant in the rheumatoid group (71% and 75%, respectively), and were decreasing in the control group (25% and 12.5%, respectively), while the A allele of rs7895833 and C allele of rs7069102 were seen less frequently in the rheumatoid group (29% and 25%, respectively) and more dominant in the control group (75% and 87.5%).</p><p>No information on the expression and function of sirtuins in RA was available until very recently. Niederer et al reported the overexpression of SIRT-1 in RA synovial tissue and despite evidence for an anti-inflammatory role of SIRT-1 in animal models of inflammation, they showed that SIRT-1 directly enhances proinflammatory cytokine production of synovial cells [<xref rid="R20" ref-type="bibr">20</xref>].</p><p>SIRT-1 deficient mice display systemic lupus erythematosus-like manifestations, suggesting that SIRT-1 may have a role in autoimmune processes. SIRT-1 targets two major proinflammatory pathways, the NF-&#x003ba;B and AP-1 pathways, both of which are implicated in the pathogenesis of chronic arthritis. Therefore, SIRT-1 may play a role in the pathogenesis of RA and other forms of arthritis. Research on SIRT-1 in arthritis is still at an early stage. The published data have confirmed that SIRT-1 is overexpressed in RA and is involved in the inflammatory process in the RA synovium.</p><p>Macrophages from myeloid SIRT-1 knockout mice showed increased inflammation produced by NF-&#x003ba;B indicating an anti-inflammatory activity of SIRT-1 [<xref rid="R21" ref-type="bibr">21</xref>].</p><p>Furthermore, the application of HDAC inhibitors causes genome-wide acetylation of histones, which improve the symptoms in lupus-prone mice [<xref rid="R22" ref-type="bibr">22</xref>] and mice induced to develop RA [<xref rid="R23" ref-type="bibr">23</xref>], while hyperacetylation of a variety of genetic loci in human SLE is associated with disease severity [<xref rid="R24" ref-type="bibr">24</xref>].</p><p>Supporting to our results studies in animal models of arthritis have shown useful effects of HDAC inhibitors; Grabiec et al evaluated the effects of different HDAC inhibitors in monocyte-derived macrophages, synovial explants and synovial fluid macrophages of patients with RA [<xref rid="R25" ref-type="bibr">25</xref>]. They used NAM, a non-specific inhibitor of sirtuins. Addition of NAM to cultured macrophages of healthy individuals reduced LPS- and TNF-&#x003b1;-induced production of IL-6 and LPS-induced TNF-&#x003b1; production. The findings of Grabiec et al were unexpected, as the data obtained with SIRT-1 deficient or SIRT-1 transgenic mice rather suggested that SIRT-1 has anti-inflammatory effects by inhibiting NF-&#x003ba;B activation. Fernandes et al have used J774 macrophages to study the effect of the sirtuin inhibitors sirtinol and cambinol. They found significantly decreased LPS-induced expression of IL-6, TNF-&#x003b1;, and the chemokine Rantes [<xref rid="R26" ref-type="bibr">26</xref>].</p><p>Studies of resveratrol in synovial cells may be of relevance for understanding the role of SIRTs in RA. Byun et al have shown that treatment of synovial fibroblasts was derived from patients with RA with resveratrol induces apoptosis. This apoptosis was independent of p53 but required activation of caspase 8 [<xref rid="R27" ref-type="bibr">27</xref>]. Also, Yang et al explored the effect of resveratrol on the levels of sirtuin 1 (SIRT-1), and they found that resveratrol increases sirtuin 1 expression in peripheral blood mononuclear cells [<xref rid="R28" ref-type="bibr">28</xref>].</p><p>No previous data associated different genotypes of SIRT-1 polymorphism with RA; we concluded that SIRT-1 polymorphisms may play a role in the development RA. Further studies are needed to explain the role of SIRT-1 in chronic joint inflammation. Moreover, research needs to concentrate on the other members of the sirtuin family. Increased understanding of the impact of sirtuins on immune pathways is needed to be able to design therapeutic strategies targeting sirtuins. In more prospective studies, the SIRT-1 gene expression and mutations should be analyzed with a bigger RA group.</p></sec></body><back><ref-list><title>References</title><ref id="R01"><label>1</label><element-citation publication-type="journal"><name><surname>Magyari</surname><given-names>L</given-names></name><name><surname>Varszegi</surname><given-names>D</given-names></name><name><surname>Kovesdi</surname><given-names>E</given-names></name><name><surname>Sarlos</surname><given-names>P</given-names></name><name><surname>Farago</surname><given-names>B</given-names></name><name><surname>Javorhazy</surname><given-names>A</given-names></name><name><surname>Sumegi</surname><given-names>K</given-names></name><etal>et al</etal><article-title>Interleukins and interleukin receptors in rheumatoid arthritis: Research, diagnostics and clinical implications</article-title><source>World J Orthop</source><year>2014</year><volume>5</volume><issue>4</issue><fpage>516</fpage><lpage>536</lpage><pub-id pub-id-type="doi">10.5312/wjo.v5.i4.516</pub-id><pub-id pub-id-type="pmid">25232528</pub-id></element-citation></ref><ref id="R02"><label>2</label><element-citation publication-type="journal"><name><surname>Huber</surname><given-names>LC</given-names></name><name><surname>Distler</surname><given-names>O</given-names></name><name><surname>Tarner</surname><given-names>I</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Pap</surname><given-names>T</given-names></name><article-title>Synovial fibroblasts: key players in rheumatoid arthritis</article-title><source>Rheumatology (Oxford)</source><year>2006</year><volume>45</volume><issue>6</issue><fpage>669</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kel065</pub-id><pub-id pub-id-type="pmid">16567358</pub-id></element-citation></ref><ref id="R03"><label>3</label><element-citation publication-type="journal"><name><surname>Guillot</surname><given-names>X</given-names></name><name><surname>Semerano</surname><given-names>L</given-names></name><name><surname>Saidenberg-Kermanac&#x02019;h</surname><given-names>N</given-names></name><name><surname>Falgarone</surname><given-names>G</given-names></name><name><surname>Boissier</surname><given-names>MC</given-names></name><article-title>Vitamin D and inflammation</article-title><source>Joint Bone Spine</source><year>2010</year><volume>77</volume><issue>6</issue><fpage>552</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.jbspin.2010.09.018</pub-id><pub-id pub-id-type="pmid">21067953</pub-id></element-citation></ref><ref id="R04"><label>4</label><element-citation publication-type="journal"><name><surname>Zarrabeitia</surname><given-names>MT</given-names></name><name><surname>Valero</surname><given-names>C</given-names></name><name><surname>Martin-Escudero</surname><given-names>JC</given-names></name><name><surname>Olmos</surname><given-names>JM</given-names></name><name><surname>Bolado-Carrancio</surname><given-names>A</given-names></name><name><surname>de Sande-Nacarino</surname><given-names>EL</given-names></name><name><surname>Rodriguez-Rey</surname><given-names>JC</given-names></name><etal>et al</etal><article-title>Association study of sirtuin 1 polymorphisms with bone mineral density and body mass index</article-title><source>Arch Med Res</source><year>2012</year><volume>43</volume><issue>5</issue><fpage>363</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.arcmed.2012.06.012</pub-id><pub-id pub-id-type="pmid">22824213</pub-id></element-citation></ref><ref id="R05"><label>5</label><element-citation publication-type="journal"><name><surname>Imai</surname><given-names>S</given-names></name><name><surname>Johnson</surname><given-names>FB</given-names></name><name><surname>Marciniak</surname><given-names>RA</given-names></name><name><surname>McVey</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>PU</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name><article-title>Sir2: an NAD-dependent histone deacetylase that connects chromatin silencing, metabolism, and aging</article-title><source>Cold Spring Harb Symp Quant Biol</source><year>2000</year><volume>65</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="doi">10.1101/sqb.2000.65.297</pub-id><pub-id pub-id-type="pmid">12760043</pub-id></element-citation></ref><ref id="R06"><label>6</label><element-citation publication-type="journal"><name><surname>Brunet</surname><given-names>A</given-names></name><name><surname>Sweeney</surname><given-names>LB</given-names></name><name><surname>Sturgill</surname><given-names>JF</given-names></name><name><surname>Chua</surname><given-names>KF</given-names></name><name><surname>Greer</surname><given-names>PL</given-names></name><name><surname>Lin</surname><given-names>Y</given-names></name><name><surname>Tran</surname><given-names>H</given-names></name><etal>et al</etal><article-title>Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase</article-title><source>Science</source><year>2004</year><volume>303</volume><issue>5666</issue><fpage>2011</fpage><lpage>2015</lpage><pub-id pub-id-type="doi">10.1126/science.1094637</pub-id><pub-id pub-id-type="pmid">14976264</pub-id></element-citation></ref><ref id="R07"><label>7</label><element-citation publication-type="journal"><name><surname>Vaziri</surname><given-names>H</given-names></name><name><surname>Dessain</surname><given-names>SK</given-names></name><name><surname>Ng Eaton</surname><given-names>E</given-names></name><name><surname>Imai</surname><given-names>SI</given-names></name><name><surname>Frye</surname><given-names>RA</given-names></name><name><surname>Pandita</surname><given-names>TK</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name><etal>et al</etal><article-title>hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase</article-title><source>Cell</source><year>2001</year><volume>107</volume><issue>2</issue><fpage>149</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(01)00527-X</pub-id><pub-id pub-id-type="pmid">11672523</pub-id></element-citation></ref><ref id="R08"><label>8</label><element-citation publication-type="journal"><name><surname>Yeung</surname><given-names>F</given-names></name><name><surname>Hoberg</surname><given-names>JE</given-names></name><name><surname>Ramsey</surname><given-names>CS</given-names></name><name><surname>Keller</surname><given-names>MD</given-names></name><name><surname>Jones</surname><given-names>DR</given-names></name><name><surname>Frye</surname><given-names>RA</given-names></name><name><surname>Mayo</surname><given-names>MW</given-names></name><article-title>Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase</article-title><source>EMBO J</source><year>2004</year><volume>23</volume><issue>12</issue><fpage>2369</fpage><lpage>2380</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7600244</pub-id><pub-id pub-id-type="pmid">15152190</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><name><surname>Cohen</surname><given-names>HY</given-names></name><name><surname>Miller</surname><given-names>C</given-names></name><name><surname>Bitterman</surname><given-names>KJ</given-names></name><name><surname>Wall</surname><given-names>NR</given-names></name><name><surname>Hekking</surname><given-names>B</given-names></name><name><surname>Kessler</surname><given-names>B</given-names></name><name><surname>Howitz</surname><given-names>KT</given-names></name><etal>et al</etal><article-title>Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase</article-title><source>Science</source><year>2004</year><volume>305</volume><issue>5682</issue><fpage>390</fpage><lpage>392</lpage><pub-id pub-id-type="doi">10.1126/science.1099196</pub-id><pub-id pub-id-type="pmid">15205477</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><name><surname>Bouras</surname><given-names>T</given-names></name><name><surname>Fu</surname><given-names>M</given-names></name><name><surname>Sauve</surname><given-names>AA</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Quong</surname><given-names>AA</given-names></name><name><surname>Perkins</surname><given-names>ND</given-names></name><name><surname>Hay</surname><given-names>RT</given-names></name><etal>et al</etal><article-title>SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><issue>11</issue><fpage>10264</fpage><lpage>10276</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408748200</pub-id><pub-id pub-id-type="pmid">15632193</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><name><surname>Simmons</surname><given-names>GE</given-names><suffix>Jr</suffix></name><name><surname>Pruitt</surname><given-names>WM</given-names></name><name><surname>Pruitt</surname><given-names>K</given-names></name><article-title>Diverse roles of SIRT1 in cancer biology and lipid metabolism</article-title><source>Int J Mol Sci</source><year>2015</year><volume>16</volume><issue>1</issue><fpage>950</fpage><lpage>965</lpage><pub-id pub-id-type="doi">10.3390/ijms16010950</pub-id><pub-id pub-id-type="pmid">25569080</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><name><surname>Colak</surname><given-names>Y</given-names></name><name><surname>Yesil</surname><given-names>A</given-names></name><name><surname>Mutlu</surname><given-names>HH</given-names></name><name><surname>Caklili</surname><given-names>OT</given-names></name><name><surname>Ulasoglu</surname><given-names>C</given-names></name><name><surname>Senates</surname><given-names>E</given-names></name><name><surname>Takir</surname><given-names>M</given-names></name><etal>et al</etal><article-title>A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators</article-title><source>J Gastrointestin Liver Dis</source><year>2014</year><volume>23</volume><issue>3</issue><fpage>311</fpage><lpage>319</lpage><pub-id pub-id-type="pmid">25267960</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><name><surname>Pasinetti</surname><given-names>GM</given-names></name><name><surname>Bilski</surname><given-names>AE</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><article-title>Sirtuins as therapeutic targets of ALS</article-title><source>Cell Res</source><year>2013</year><volume>23</volume><issue>9</issue><fpage>1073</fpage><lpage>1074</lpage><pub-id pub-id-type="doi">10.1038/cr.2013.94</pub-id><pub-id pub-id-type="pmid">23856645</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><name><surname>Kong</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Luo</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>Y</given-names></name><name><surname>Miao</surname><given-names>L</given-names></name><name><surname>Cai</surname><given-names>L</given-names></name><article-title>Sirtuin 1: a target for kidney diseases</article-title><source>Mol Med</source><year>2015</year><volume>21</volume><fpage>87</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.2119/molmed.2014.00211</pub-id><pub-id pub-id-type="pmid">25587857</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><name><surname>Rahman</surname><given-names>I</given-names></name><name><surname>Kinnula</surname><given-names>VL</given-names></name><name><surname>Gorbunova</surname><given-names>V</given-names></name><name><surname>Yao</surname><given-names>H</given-names></name><article-title>SIRT1 as a therapeutic target in inflammaging of the pulmonary disease</article-title><source>Prev Med</source><year>2012</year><volume>54</volume><issue>Suppl</issue><fpage>S20</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1016/j.ypmed.2011.11.014</pub-id><pub-id pub-id-type="pmid">22178470</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><name><surname>Abourazzak</surname><given-names>FE</given-names></name><name><surname>Talbi</surname><given-names>S</given-names></name><name><surname>Aradoini</surname><given-names>N</given-names></name><name><surname>Berrada</surname><given-names>K</given-names></name><name><surname>Keita</surname><given-names>S</given-names></name><name><surname>Hazry</surname><given-names>T</given-names></name><article-title>25-Hydroxy vitamin D and its relationship with clinical and laboratory parameters in patients with rheumatoid arthritis</article-title><source>Clin Rheumatol</source><year>2015</year><volume>34</volume><issue>2</issue><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1007/s10067-014-2713-0</pub-id><pub-id pub-id-type="pmid">24924607</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><name><surname>Aguado</surname><given-names>P</given-names></name><name><surname>Garces</surname><given-names>MV</given-names></name><name><surname>Gonzalez Casaus</surname><given-names>ML</given-names></name><name><surname>del Campo</surname><given-names>MT</given-names></name><name><surname>Richi</surname><given-names>P</given-names></name><name><surname>Coya</surname><given-names>J</given-names></name><name><surname>Torrijos</surname><given-names>A</given-names></name><etal>et al</etal><article-title>[High prevalence of vitamin D deficiency in postmenopausal women at a rheumatology office in Madrid. Evaluation of 2 vitamin D prescription regimens]</article-title><source>Med Clin (Barc)</source><year>2000</year><volume>114</volume><issue>9</issue><fpage>326</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1016/S0025-7753(00)71283-8</pub-id><pub-id pub-id-type="pmid">10786331</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><name><surname>Feser</surname><given-names>M</given-names></name><name><surname>Derber</surname><given-names>LA</given-names></name><name><surname>Deane</surname><given-names>KD</given-names></name><name><surname>Lezotte</surname><given-names>DC</given-names></name><name><surname>Weisman</surname><given-names>MH</given-names></name><name><surname>Buckner</surname><given-names>JH</given-names></name><name><surname>Mikuls</surname><given-names>T</given-names></name><etal>et al</etal><article-title>Plasma 25,OH vitamin D concentrations are not associated with rheumatoid arthritis (RA)-related autoantibodies in individuals at elevated risk for RA</article-title><source>J Rheumatol</source><year>2009</year><volume>36</volume><issue>5</issue><fpage>943</fpage><lpage>946</lpage><pub-id pub-id-type="doi">10.3899/jrheum.080764</pub-id><pub-id pub-id-type="pmid">19286844</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><name><surname>Donmez</surname><given-names>G</given-names></name><name><surname>Guarente</surname><given-names>L</given-names></name><article-title>Aging and disease: connections to sirtuins</article-title><source>Aging Cell</source><year>2010</year><volume>9</volume><issue>2</issue><fpage>285</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1111/j.1474-9726.2010.00548.x</pub-id><pub-id pub-id-type="pmid">20409078</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><name><surname>Niederer</surname><given-names>F</given-names></name><name><surname>Ospelt</surname><given-names>C</given-names></name><name><surname>Brentano</surname><given-names>F</given-names></name><name><surname>Hottiger</surname><given-names>MO</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Detmar</surname><given-names>M</given-names></name><etal>et al</etal><article-title>SIRT1 overexpression in the rheumatoid arthritis synovium contributes to proinflammatory cytokine production and apoptosis resistance</article-title><source>Ann Rheum Dis</source><year>2011</year><volume>70</volume><issue>10</issue><fpage>1866</fpage><lpage>1873</lpage><pub-id pub-id-type="doi">10.1136/ard.2010.148957</pub-id><pub-id pub-id-type="pmid">21742641</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><name><surname>Schug</surname><given-names>TT</given-names></name><name><surname>Xu</surname><given-names>Q</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Peres-da-Silva</surname><given-names>A</given-names></name><name><surname>Draper</surname><given-names>DW</given-names></name><name><surname>Fessler</surname><given-names>MB</given-names></name><name><surname>Purushotham</surname><given-names>A</given-names></name><etal>et al</etal><article-title>Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress</article-title><source>Mol Cell Biol</source><year>2010</year><volume>30</volume><issue>19</issue><fpage>4712</fpage><lpage>4721</lpage><pub-id pub-id-type="doi">10.1128/MCB.00657-10</pub-id><pub-id pub-id-type="pmid">20647536</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><name><surname>Mishra</surname><given-names>N</given-names></name><name><surname>Reilly</surname><given-names>CM</given-names></name><name><surname>Brown</surname><given-names>DR</given-names></name><name><surname>Ruiz</surname><given-names>P</given-names></name><name><surname>Gilkeson</surname><given-names>GS</given-names></name><article-title>Histone deacetylase inhibitors modulate renal disease in the MRL-lpr/lpr mouse</article-title><source>J Clin Invest</source><year>2003</year><volume>111</volume><issue>4</issue><fpage>539</fpage><lpage>552</lpage><pub-id pub-id-type="doi">10.1172/JCI16153</pub-id><pub-id pub-id-type="pmid">12588892</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><name><surname>Nishida</surname><given-names>K</given-names></name><name><surname>Komiyama</surname><given-names>T</given-names></name><name><surname>Miyazawa</surname><given-names>S</given-names></name><name><surname>Shen</surname><given-names>ZN</given-names></name><name><surname>Furumatsu</surname><given-names>T</given-names></name><name><surname>Doi</surname><given-names>H</given-names></name><name><surname>Yoshida</surname><given-names>A</given-names></name><etal>et al</etal><article-title>Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression</article-title><source>Arthritis Rheum</source><year>2004</year><volume>50</volume><issue>10</issue><fpage>3365</fpage><lpage>3376</lpage><pub-id pub-id-type="doi">10.1002/art.20709</pub-id><pub-id pub-id-type="pmid">15476220</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><name><surname>Nambiar</surname><given-names>MP</given-names></name><name><surname>Warke</surname><given-names>VG</given-names></name><name><surname>Fisher</surname><given-names>CU</given-names></name><name><surname>Tsokos</surname><given-names>GC</given-names></name><article-title>Effect of trichostatin A on human T cells resembles signaling abnormalities in T cells of patients with systemic lupus erythematosus: a new mechanism for TCR zeta chain deficiency and abnormal signaling</article-title><source>J Cell Biochem</source><year>2002</year><volume>85</volume><issue>3</issue><fpage>459</fpage><lpage>469</lpage><pub-id pub-id-type="doi">10.1002/jcb.10160</pub-id><pub-id pub-id-type="pmid">11967985</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><name><surname>Grabiec</surname><given-names>AM</given-names></name><name><surname>Krausz</surname><given-names>S</given-names></name><name><surname>de Jager</surname><given-names>W</given-names></name><name><surname>Burakowski</surname><given-names>T</given-names></name><name><surname>Groot</surname><given-names>D</given-names></name><name><surname>Sanders</surname><given-names>ME</given-names></name><name><surname>Prakken</surname><given-names>BJ</given-names></name><etal>et al</etal><article-title>Histone deacetylase inhibitors suppress inflammatory activation of rheumatoid arthritis patient synovial macrophages and tissue</article-title><source>J Immunol</source><year>2010</year><volume>184</volume><issue>5</issue><fpage>2718</fpage><lpage>2728</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.0901467</pub-id><pub-id pub-id-type="pmid">20100935</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><name><surname>Fernandes</surname><given-names>CA</given-names></name><name><surname>Fievez</surname><given-names>L</given-names></name><name><surname>Neyrinck</surname><given-names>AM</given-names></name><name><surname>Delzenne</surname><given-names>NM</given-names></name><name><surname>Bureau</surname><given-names>F</given-names></name><name><surname>Vanbever</surname><given-names>R</given-names></name><article-title>Sirtuin inhibition attenuates the production of inflammatory cytokines in lipopolysaccharide-stimulated macrophages</article-title><source>Biochem Biophys Res Commun</source><year>2012</year><volume>420</volume><issue>4</issue><fpage>857</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2012.03.088</pub-id><pub-id pub-id-type="pmid">22469470</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><name><surname>Byun</surname><given-names>HS</given-names></name><name><surname>Song</surname><given-names>JK</given-names></name><name><surname>Kim</surname><given-names>YR</given-names></name><name><surname>Piao</surname><given-names>L</given-names></name><name><surname>Won</surname><given-names>M</given-names></name><name><surname>Park</surname><given-names>KA</given-names></name><name><surname>Choi</surname><given-names>BL</given-names></name><etal>et al</etal><article-title>Caspase-8 has an essential role in resveratrol-induced apoptosis of rheumatoid fibroblast-like synoviocytes</article-title><source>Rheumatology (Oxford)</source><year>2008</year><volume>47</volume><issue>3</issue><fpage>301</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1093/rheumatology/kem368</pub-id><pub-id pub-id-type="pmid">18276737</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>WB</given-names></name><name><surname>Li</surname><given-names>QP</given-names></name><name><surname>Kang</surname><given-names>L</given-names></name><name><surname>Lei</surname><given-names>XP</given-names></name><name><surname>Zhang</surname><given-names>LY</given-names></name><name><surname>Lu</surname><given-names>YY</given-names></name><etal>et al</etal><article-title>[Resveratrol increases sirtuin 1 expression in peripheral blood mononuclear cells of premature infants and inhibits the oxidative stress induced by hyperoxia in vivo]</article-title><source>Zhongguo Dang Dai Er Ke Za Zhi</source><year>2016</year><volume>18</volume><issue>1</issue><fpage>72</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">26781417</pub-id></element-citation></ref></ref-list></back></article>